There were 1,922 press releases posted in the last 24 hours and 399,241 in the last 365 days.

MariamTek Boosts Royalty Payments for Promotional License Holders

Catalysts of Revolutionary Health-Tech

Catalysts of Revolutionary Health-Tech

MariamTek, a pioneering force at the crossroads of healthcare solutions, announces an exciting update, reaffirming commitment to innovation and shared success.

MariamTek is dedicated to revolutionizing healthcare through innovative solutions, particularly in diabetes treatment and cardiology.”
— Anjo De Heus
BARRINGTON, ILLINOIS, UNITED STATES, March 12, 2024 / -- MariamTek, Inc., a pioneering force at the crossroads of healthcare and environmental solutions, proudly announces an exciting update for its promotional license holders, reaffirming its commitment to innovation and shared success.

Effective March 13th, 2024, MariamTek will significantly increase its royalty payments to $4 per license for all promotional license holders, doubling the previous rate from $20 to $40. This enhancement underscores the company's exceptional growth trajectory and the establishment of robust revenue streams.

Under the visionary leadership of the MariamTek team, the company continues to lead the charge in revolutionizing biotechnology and environmental sectors. Noteworthy achievements include the strategic spin-off of Diabetes Actual as a standalone ILOCX listing, the acquisition of the revenue-positive Cardiology Institute of America, and strategic collaborations with industry leaders such as Advanced Medical Solutions International (AMSI), MaxClean 756, ConFlow Power and Cytometix.

These milestones highlight MariamTek's unwavering commitment to addressing critical healthcare and environmental challenges, driving both societal impact and financial success through innovative solutions and strategic partnerships. The increased royalty payments underscore MariamTek's appreciation for the trust and engagement of its promotional license holders.

Dr. Holterman, CEO of MariamTek, stated, "MariamTek's strategy is clear – to find profitable solutions for the world's most pressing challenges and ensure our partners share in the success. This royalty increase reflects our commitment to this strategy, recognizing the invaluable support of our license holders and reinforcing our shared journey towards a healthier and more sustainable future."

Anjo De Heus, Chief Strategy Officer at MariamTek, added, "MariamTek is dedicated to revolutionizing healthcare through innovative solutions, particularly in diabetes treatment and cardiology, where we are driving significant advancements to improve patient outcomes and quality of life."

With a diverse portfolio spanning diabetes care, cardiology, environmental hygiene, green energy solutions, and advanced medical technologies, MariamTek exemplifies a holistic approach to global health and environmental sustainability. Positioned for continued growth and impact, MariamTek remains committed to driving innovation and fostering transformative technologies that enhance healthcare delivery worldwide.

For more information about MariamTek, its portfolio, and its impact on healthcare and the environment, please visit MariamTek's official website.

About MariamTek:
MariamTek, Inc., founded in 2018 and headquartered in Barrington, Illinois, is a leader in developing and implementing solutions to the most challenging issues in healthcare and the environment. Led by a seasoned management team, MariamTek partners with innovative companies to bring transformative solutions to market. At MariamTek Inc., our mission is to revolutionize the healthcare industry by investing in and actively nurturing groundbreaking health-tech solutions. We are committed to driving innovation and fostering the development of transformative technologies that improve patient outcomes and enhance healthcare delivery worldwide.

Anjo De Heus
MariamTek Inc.
Visit us on social media: